Neelum Aggarwal

, MD, FAMWA

Professor, Neurological Sciences, Rush Alzheimer's Disease Center / Research Director, Rush Heart Center for Women, Rush University

Neelum Aggarwal, MD, FAMWA, is a professor in the Department of Neurological Sciences at the Rush Alzheimer’s Disease Center and Research Director for the Rush Heart Center for Women. She is also the senior cognitive neurologist for the NIA-funded Rush Alzheimer’s Disease Research Center and Site Principal Investigator and Steering Committee member for the Alzheimer’s Clinical Trial Consortium. Her recent clinical and research interests lie in the diagnosis and clinical management of cognitive change and dementia prevention by identifying how risk factors for cardiovascular disease and stroke—including genetics and blood and neuroimaging biomarkers—vary by race/ethnicity and sex and gender. She has served in numerous leadership roles throughout her career. She is the Chief Diversity and Inclusion Officer for the American Medical Women’s Association (AMWA), AMWA Delegate to the American Medical Association (AMA), past chair of the AMA – Women’s Physician Section, and past recipient of the 2022 Rush Excellence in Research Award and the 2016 AMWA Women in Science Award. She has also served as the co-chair for the Alzheimer’s Association – ISTAART Sex Differences and Diversity special interest group and is a member of the Society of Women’s Health Research Alzheimer’s Disease Interdisciplinary Network.  

Read more

This Speaker's Sessions

PANEL
Thursday Oct. 17
-
2:00–2:50 PM ET
Watch Replay
Now Live!

Implementing an Effective and Inclusive Biomarker Strategy

Not all brains are the same. This panel will explore how experts evaluate blood biomarker accuracy in diverse real-world populations, including individuals of different races and ethnicities, and those with comorbidities that may affect readings or symptom severity. We will discuss how doctors communicate these results and assess whether we are ready to implement these diagnostics across all populations. Key Question: Are we ready to implement diagnostics across all populations?

View SessionWatch Replay